No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
INO Inovio Pharmaceuticals
- 8.5600
- -0.3800-4.25%
Close Jun 18 16:00 ET
221.80MMarket Cap-1553P/E (TTM)
8.9400High8.5500Low291.98KVolume8.9400Open8.9400Pre Close2.53MTurnover1.15%Turnover RatioLossP/E (Static)25.91MShares14.748052wk High2.35P/B218.24MFloat Cap3.888052wk Low--Dividend TTM25.49MShs Float2352.0000Historical High--Div YieldTTM4.36%Amplitude3.8880Historical Low8.6520Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
PLYMOUTH MEETING, Pa., June 4, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Better Buy: Inovio Pharmaceuticals Vs. Novavax
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 2nd Annual BioConnect Investor Conference (Transcript)
Comments
$Inovio Pharmaceuticals(INO.US$ INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
$Inovio Pharmaceuticals(INO.US$ Inovio Pharmaceuticals Inc - Pricing of an Underwritten Offering of 2.5 Mln Shares of Its Common Stock at an Offering Price of $7.693 per Share
2
$Inovio Pharmaceuticals(INO.US$ Inovio Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Inovio Pharmaceuticals' surplus of liquid assets over total liabilities indicates a conservative balance sheet, but its EBIT level loss and significant revenue drop are concerning. Caution is advised until positive free cash flow is seen.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg